Thromboelastographic monitoring of fondaparinux in surgical patients

Fondaparinux is currently the first therapeutic choice in several clinical settings such as deep venous thrombosis (DVT) prophylaxis in orthopedics or in cases of acute coronary syndromes. The main drawback of FOND is that routine monitoring is not currently available. This could be a problem during the management of critical and surgical patients, especially in cases of old patients and renal failure. The aim of this study is to evaluate the ability of thromboelastography (TEG) to determine the level of anticoagulation due to FOND in a surgical population.